Utilization of the Oncotype Dx Assay for Young Patients with Early Stage, Hormone-Receptor Positive, HER2-Negative Breast Cancer in an Integrated Health System

被引：0
|
作者：
Aller, Ashley
Darbinian, Jeanne A.
Liu, Raymond
Kuehner, Gillian
Savitz, Alison
Odele, Patience
Habel, Laurel
Vuong, Brooke
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-27
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer
    Lopez, M.
    Di Lauro, L.
    Viola, G.
    Foggi, P.
    Conti, F.
    Corsetti, S.
    Sergi, D.
    Botti, C.
    Di Filippo, F.
    Vici, P.
    CLINICA TERAPEUTICA, 2009, 160 (06): : 481 - 488
  • [2] Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer
    Besnainou, Hanna
    Cabel, Luc
    BULLETIN DU CANCER, 2024, 111 (04) : 333 - 334
  • [3] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    BREAST CARE, 2024, 19 (01) : 27 - 33
  • [4] Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
    Abdelmaksoud, Bader A.
    Toam, Mostafa M.
    Fayed, Alaa A.
    BREAST CANCER MANAGEMENT, 2019, 8 (03)
  • [5] Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
    Parati, Maria Chiara
    Pedersini, Rebecca
    Perego, Gianluca
    Reduzzi, Roberto
    Savio, Tommaso
    Cabiddu, Mary
    Borgonovo, Karen
    Ghilardi, Mara
    Luciani, Andrea
    Petrelli, Fausto
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 101 - 111
  • [6] Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC)
    Lau, A.
    Miller, D.
    Davison, D.
    Rothney, M.
    Borgen, P.
    BREAST, 2017, 32 : S97 - S97
  • [7] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [8] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [9] Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania
    Erb, C.
    Fox, K. R.
    Patel, M.
    Hook, K.
    DeMichele, A.
    Kaplan, C.
    Domchek, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S154 - S154
  • [10] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
    Meisel, Jane
    Zhang, Chao
    Neely, Cameron
    Menduza, Pia
    You, Shuo
    Han, Tatiana
    Liu, Yuan
    Sahin, Aysegul A.
    O'Regan, Ruth
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
12345